Human pancreas studies refine understanding of type 1 diabetes progression

This review synthesizes findings from human pancreas and pancreas-draining lymph-node studies in type 1 diabetes (T1DM). It highlights how access to human tissue, high-resolution imaging, single-cell and spatial multi-omics, and AI-assisted histopathology have shifted research toward examining disease directly in people. The source does not report a pooled sample size or new clinical study results.

The studies reviewed suggest that β-cell loss or dysfunction may begin earlier than previously recognized, with small β-cell-rich islets and insulin-positive cell clusters preferentially affected. Larger islets may show transient resistance, and substantial β-cell mass can remain at diagnosis despite impaired function. Across disease stages, β-cells show molecular patterns including interferon signalling, increased antigen presentation and adaptive immune-evasion programmes. Pancreatic lymph-node studies also report early immune dysregulation, including altered regulatory T-cell signatures and expansion of stem-like cytotoxic T-cell populations before overt hyperglycaemia.

These findings support an integrated model linking disease stage with changing β-cell and immune phenotypes. They are based on tissue research and do not establish a clinical intervention or change to current practice; the review also emphasizes heterogeneity by age, disease duration and immune context.